First Oral Drug for Secondary Progressive MS Tops SPT Week in Review
Top news of the week from Specialty Pharmacy Times.
5. Study Supports Comparable Efficacy of Generic and Brand-Name Drugs for Chronic Conditions
The findings could help promote interventions aimed at improving patient and provider confidence in generic drugs for managing chronic diseases. Read more.
4. Long-standing Drug Treatment May Prolong Life for MS Patients
Study is the first and largest of its kind to examine mortality associated with beta interferons, the first drugs to be approved for the treatment of relapsing-onset multiple sclerosis. Read more.
3. Combined Immunosuppression Effective for Older Patients with Crohn Disease
Study finds older patients administered combined immunosuppression experienced similar remission of Crohn disease as those aged under 60 years. Read more.
2. FDA Approves First Treatment for Non-Radiographic Axial Spondyloarthritis
Certolizumab pegol (Cimzia) is the first FDA-approved therapy for this type of axial spondyloarthritis, filling an unmet clinical need for treatment options. Read more.
1. FDA OKs Siponimod, First Oral Drug for Active Secondary Progressive MS
Novartis’ siponimod (Mayzent) is approved for adults with active secondary progressive multiple sclerosis, clinically isolated syndrome, and relapsing-remitting disease. Read more.